cetuximab,encorafenib,capecitabine,bevacizumab
roche,pfizer,eli lilly
['rectal', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'cetuximab', 'bevacizumab', 'capox', 'enco ', 'encorafenib', 'colorectal', 'imab ']
 great discussion &amp; comments. this has led to this ongoing global #breakwater study. safety lead in data just presented as well. looking at doublet (enco cetuximab) +/-chemo to potentially kill resistance clones and/or synergy with chemo. #crcsm #colorectalcancer #brafv600e 
Oncologist | Researcher | ColorectalCancer #CRCSM👨🏼‍🎓@MayoClinic @PittTweet Alum; 🧬#ctDNA #LiquidBiopsies💡#PrecisionOncology ViewsMy Own. COI @ASCO📍 #GI23